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ABSTRACT
The transcription factor Hypoxia-inducible factor 1
(HIF-1) plays a central role in the transcriptional
response to oxygen flux. To gain insight into
the molecular pathways regulated by HIF-1, it is
essential to identify the downstream-target genes.
We report here a strategy to identify HIF-1-target
genes based on an integrative genomic approach
combining computational strategies and experi-
mental validation. To identify HIF-1-target genes
microarrays data sets were used to rank genes
based on their differential response to hypoxia.
The proximal promoters of these genes were then
analyzed for the presence of conserved HIF-1-
-binding sites. Genes were scored and ranked
based on their response to hypoxia and their HIF-
binding site score. Using this strategy we recovered
41% of the previously confirmed HIF-1-target genes
that responded to hypoxia in the microarrays and
provide a catalogue of predicted HIF-1 targets.
We present experimental validation for ANKRD37
as a novel HIF-1-target gene. Together these analy-
ses demonstrate the potential to recover novel
HIF-1-target genes and the discovery of mamma-
lian-regulatory elements operative in the context of
microarray data sets.
INTRODUCTION
Maintenance of oxygen homeostasis in mammalian cells
is fundamental to the survival of the organism. One of
the pivotal mediators of the cellular response to hypoxia
is hypoxia-inducible factor (HIF), a transcription factor
that contains a basic helix-loop-helix motif as well as
PAS domain. There are three known members of the
HIF family (HIF-1, HIF-2 and HIF-3) and all are a/b
heterodimeric proteins. HIF-1 was the ﬁrst factor to be
cloned and is the best understood isoform (1). HIF-3 is
a distant relative of HIF-1 and little is currently known
about its function and involvement in oxygen homeosta-
sis. HIF-2, however, is closely related to HIF-1 and both
activate hypoxia-dependent gene transcription. In all three
isoforms the a-subunit senses oxygen levels (2–5). In nor-
moxia the a-subunit is ubiquitously expressed but is rap-
idly degraded through interaction with the VHL ubiquitin
ligase complex (6). In hypoxic conditions, it is stabilized
through multiple mechanisms that are transcriptional,
post-transcriptional, as well as post-translational (6–9).
The b-subunit is widely expressed and generally not
regulated by hypoxia. Once stabilized HIF-1 and HIF-2
interact with co-activators such as CREBBP/EP300 and
bind to a consensus sequence element (50-RCGTG-30)i n
the proximal promoters of hypoxia-regulated genes.
Together these genes control cellular process including
a switch from oxidative to glycolytic metabolism, inhibi-
tion of cellular proliferation, and stimulation of oxygen
delivery through erythropoiesis and angiogenesis (10).
Metabolic deregulation is the ﬁnal outcome if the adaptive
response is inadequate.
Hypoxia can arise in a variety of developmental, phys-
iological and pathological states. Solid tumors, such as
breast cancer, quickly outgrow their blood supply and
manipulate the hypoxia pathways to promote their own
survival. The role of HIF-1 in tumor onset, progression,
invasion and metastasis has been demonstrated in
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regulatory roles for HIF-2 have been demonstrated in an
expanding list of cancers (13). For instance, in clear renal
cell carcinoma the normal predominance of HIF1A
expression is altered in favor of EPAS1 (HIF2a) expres-
sion and promotes prosurvival rather than proapoptotic
factors (14,15). As a result HIF-target genes have emerged
as potential targets for cancer speciﬁc therapy (16,17).
HIF-1 is an important metabolic regulator that allows
rapid adaptation to oxygen availability. This eﬀect is
mediated through key regulators of bioenergetics and
growth. For instance, PDK1 is directly induced by HIF-1
resulting in attenuation of mitochondrial function and
oxygen consumption (18) and CDKN1A is induced leading
to growth arrest at the G1 phase (19). Identifying
such HIF-target genes is central to our understanding
of the HIF network and the mechanism of cellular path-
ways modulation during hypoxia. In addition, identifying
additional binding sites in HIF-regulated genes might
contribute to the paradigm of inferring function from
sequence.
Currently, studies attempting to identify novel HIF-
target genes rely on microarray expression proﬁles to
detect genes that respond to changes in HIF protein
levels. Typically a gene of interest is selected and experi-
mentally validated for HIF binding to its promoter. Kim
et al. identiﬁed 25 transcripts that increase by at least
4-fold during hypoxia in a B cell line. PDK1 was selected
for further validation due to its role in regulating the TCA
cycle. Consequently they were able to show that HIF-1
binds to the PDK1 promoter (18). Shen et al. (20) used
a more rationale microarray design where tissues from
Caenorhabditis elegans were proﬁled in normoxia and in
hypoxia in a wild-type, HIF-1 knockout and a VHL
mutant strain. This study resulted in 63 HIF-1 dependent
genes that respond to hypoxia but only 12 of those had a
human homolog. Elvidge et al. (21) compared expression
proﬁles of human breast cancer cells in normoxia, hypoxia
and in normoxia treated with a 2-OG-dependent dioxy-
genase inhibitor, dimethyloxalylglycine (DMOG) which
activates HIF-1. In addition, they compared expression
proﬁles in hypoxia and in hypoxia treated with siRNAs
to HIF1A and EPAS1 (HIF-2a). Manalo et al. (22) pro-
ﬁled arterial endothelial cells in normoxia and in hypoxia
as well as in normoxia in the presence of a HIF-1a con-
stitutively active form. Only 45 genes were identiﬁed in
both studies as HIF-1 dependent. Although these
approaches are more likely to ﬁlter out genes that are
not dependent on HIF-1, it remains challenging to deter-
mine whether the aﬀected transcripts were directly or
indirectly modulated by HIF.
Several methods for in-silico identiﬁcation of tran-
scription factor-binding sites (TFBS) have been proposed
(23–29). These methods fall into two categories. First,
identiﬁcation of TFBS based on predeﬁned position
weight matrices (PWM). Second, de novo prediction of
sequence motifs over-represented in proximal promoters
compared to control sequences [for a review, see (30,31)].
Examples for the former include STORM in CREAD
(27), CORE_TF (28) and GeneAct (29) and for the
latter DME (32) and the genomic identiﬁcation of motifs
described by Xie et al. (26). PWMs of HIF-1 have been
previously used to identify genome-wide target genes. For
instance, the Gene Set Enrichment Analysis program con-
tains a set of HIF-1-target genes as part of its Molecular
Signature Database (26,33). However, these approaches
do not take into consideration promoter availability.
In addition, the consensus HIF-binding sequence is very
short, has low information content and is ubiquitously
present in the human genome making in-silico genome-
wide prediction unreliable. To generate a reliable predic-
tion we propose to reduce the search space to a subset
of genes expressed in speciﬁc tissues under speciﬁc condi-
tions. This can be achieved by microarray expression pro-
ﬁles under the assumption that promoters of genes that
respond to a stimulus are available for TF binding.
Several groups previously demonstrated that microarray
expression proﬁles can be used to improve TFBS predic-
tion (32,34–36) and that cis-regulatory modules in proxi-
mal promoters correlate with diﬀerential expression of
downstream-target genes (27).
In this study we present an integrative genomic
approach combining both computational and experimen-
tal strategies to identify HIF-target genes. Using this
approach we recovered 41% of the known HIF-1-target
genes that were diﬀerentially expressed in hypoxia, deﬁned
a ranked list of HIF-target genes and experimentally vali-
dated ANKRD37 as a novel HIF-1 target.
MATERIALS AND METHODS
Microarrays
Raw microarray data was obtained from GEO (37) and
ArrayExpress (38). Microarray studies were ﬁltered to
identify those that proﬁled the same tissue in normoxia
and hypoxia on Aﬀymetrix platform and used at least
two replicates and provided raw data. Aﬀymetrix-based
data sets were normalized using the GCRMA module
(39) of bioconductor (40) and present–absent calls were
calculated for each probe using the MAS5 module. All
probes with no present calls were removed and from the
remaining at least one sample was required to have an
expression value larger than log2 (100), as recommended
by Aﬀymetrix. In all experiments, only pairwise compar-
isons were made with respect to normoxia. After the initial
ﬁltering was applied, the expression values were centered
to the mean for each probe with replicates. Only probes
for which the expression values of the replicates were all
positive or all negative were further tested for diﬀerential
expression. The Limma module (41) of biocoductor was
used to ﬁt a linear model for each probe and P-values were
corrected using the false discovery rate method (42).
Promoters
Promoter sequences of human genome build 18 were
obtained from UCSC genome browser (43). For each pro-
tein-coding gene, the proximal promoter was deﬁned
as 700 bases upstream and 300 bases downstream of
the transcription start site. In cases where multiple tran-
scripts were annotated all alternative promoters were
obtained and analyzed individually. Due to restriction of
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strand sequence of the genome was used. Background
promoters for enrichment analysis were selected randomly
from the promoter collection to match the CpG content
and base composition of the foreground promoters. We
obtained CpG sequence location from UCSC genome
browser (43) and matched their location to the promoters
deﬁned. Each promoter was classiﬁed as CpG or non-CpG
and for the background set the same proportion of CpG
and non CpG promoters were selected randomly accord-
ing to the ratio in the foreground set. Next we veriﬁed that
the base composition matched within  2% for each
nucleotide with the foreground data set. For all enrich-
ment purposes a set of 1000 promoters was used as a
background.
Enrichment of binding sites
The program MOTIFCLASS v1.40 (27) was employed to
identify binding sites over-represented in promoters of a
foreground set (genes diﬀerentially expressed in micro-
arrays) compared to a background set of 1000 randomly
selected promoters. The relative error-rate was optimized
for each motif and a P-value was calculated using 10000
permutations. Finally, only motifs with an enrichment
speciﬁcity of at least 0.5 were reported.
De-novo prediction of motifs
The program DME (v2.0) (27,32) was employed using the
ZOOPS model to identify motifs of length 5–12 bases
compared to a background set. Only the top 50 enriched
motifs were reported and compared to known motifs using
the program MATCOMPARE in CREAD (27).
Binding site prediction
The program STORM in CREAD (27,44) was used to
match PWMs to genomic DNA and was employed using
a P-value cutoﬀ of 1e-4. This cutoﬀ was found to be opti-
mal since a cutoﬀ of P<1e–3 was not stringent enough
predicting nearly every promoter in the genome as having
a HIF-1 site while P<1e–5 was too stringent predicting
only a handful of promoters in the genome with a HIF-1
site. Conservation information of 28 species genome align-
ments (43) was used in two approaches. First, the software
multiSTORM [also in CREAD (27)] was employed to
identify the number of genomes in which the PWM
could still be matched with the same P-value cutoﬀ as
used in STORM. Second, the software site-cons was
employed to calculate the level of conservation at each
binding site compared to the ﬂanking 100 bases (27).
The site-cons P-value was obtained by extracting 100
bases upstream and downstream of the binding site and
sampling randomly a number of columns equal to the
length of the predicted binding site. A conservation
score was then calculated for these columns and the pro-
cess was iterated 10000 times to obtain a distribution.
Finally, the P-value was calculated by comparing the orig-
inal score for the binding site to the distribution.
Conservation information was obtained from the
28-genome alignments available at UCSC genome brow-
ser (43). Namely, human (hg18), chimpanzee (panTro2),
rhesus (rheMac2), bushbaby (otoGar1), tree shrew
(tupBel1), mouse (mm8), rat (rn4), guinea pig (cavPor2),
rabbit (oryCun1), shrew (sorAra1), hedgehog (eriEur1),
dog (canFam2), cat (felCat3), horse (equCab1), cow
(bosTau3), armadillo (dasNov1), elephant (loxAfr1),
tenrec (echTel1), opossum (monDom4), platypus
(ornAna1), lizard (anoCar1), chicken (galGal3), frog
(xenTro2), fugu (fr2), tetraodon (tetNig1), stickleback
(gasAcu1), medaka (oryLat1) and zebraﬁsh (danRer4).
Transcription network
For each predicted HIF-target gene, the single best scoring
HIF site was selected and other binding sites were identi-
ﬁed within  25,  50,  75,  100,  125 and  150 bases
of that site as well as in the entire promoter. To obtain a
P-value the frequency of each site within that window was
compared to a randomly selected background set of 1000
promoters from genes that respond to hypoxia but had
no detectable HIF-binding site. Sequence composition
for the foreground and background set were matched as
described above. In each of the background promoters a
single binding site was randomly selected and binding sites
were identiﬁed within the window size as selected for the
HIF site. A chi-square test was performed for each TF,
comparing the occurrence of binding sites in the neighbor-
hood of HIF to their occurrence in the neighborhood
of the randomly selected binding site in the background
set. This process was iterated 100 times and the average
P-value for each TFBS was used as the ﬁnal P-value.
No correction for P-values was performed.
Functional pathway analysis
The KEGG database (release 47) (45) was obtained
and used to place predicted HIF-target genes into molec-
ular pathways. Statistical analysis was performed using
a hypergeometric distribution as described in the
GOhyperGAll module of Bioconductor for gene ontology
terms (40). The R program was employed (v2.6.2) with the
following command: phyper(x 1, m, n–m, k and
lower.tail=FALSE), where x is the number of predicted
target gene within a speciﬁc pathway; m, the number of
genes in that pathway; n total number of unique genes
in KEGG; and k, the number of predicted HIF-target
genes that have an entry in any of the KEGG pathways.
P-values were not corrected for multiple testing. This sta-
tistical analysis was repeated using the Reactome pathway
database (46), the curated gene sets of Gene Set
Enrichment Molecular Signature database (33) and the
microRNA predicted targets database TargetScan (47).
Enrichment for protein interactions was performed by
ﬁrst compiling a list of interactors for each human protein
(Data obtained from NCBI Gene database). The
HomoloGene database (48) was used to identify interac-
tion in other species that can be mapped to human pro-
teins. Finally, enrichment was calculated as described for
KEGG by considering all interactors of each protein.
Protein domains were obtained from Interpro (49) and
enrichment was calculated for each domain.
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Genes that localize to the mitochondria were selected by
identifying (i) all human Swiss-Prot proteins annotated as
localized to the mitochondria (50); (ii) genes annotated
with Gene Ontology terms that include the keywords:
mitochondria, mitochondrion or mitochondrial (51); and
(iii) A predicted catalog of genes localized to the mito-
chondria (52). Genes from the predicted list of mitochon-
drial genes that conﬂicted with existing knowledge and
annotation were removed.
Cell culture
DLD-1, HCT116, SW480, Lovo, Panc-1, HeLa and
MCF7 cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS). Hypoxic conditions were achieved by
culturing cell lines in a sealed hypoxia chamber (Billups-
Rothenberg) for 18h after ﬂushing with a mixture of 1%
O2,5 %C O 2 and 94% N2 (Compressed pre-mixed gas,
Airgas) (53). To minimize the eﬀect of serum growth fac-
tors, the culture medium was switched to serum-free
UltraCulture (Lonza) before the cells were subjected to
hypoxia.
Quantitative polymerase chain reaction analysis (qPCR)
Total RNA was isolated from cultured cells using the
RNeasy kit (Qiagen) and reverse transcription with
random hexanucleotide primers and SuperScript Reverse
Transcriptase III (Invitrogen) was performed. The result-
ing cDNA was ampliﬁed by real-time polymerase chain
reaction using the iQ5 Real-Time PCR Detection System
(BioRad) and Power SYBR Green PCR Master Mix
(Applied Biosystems). Primer sequences were 50-GTCGC
CTGTCCACTTAGCC-30 and 50-GCTGTTTGCCCGTT
CTTATTACA-30 for ANKRD37,5 0-AGGCCAGCACAT
AGGAGAGA-30 and 50-TTTCTTGCGCTTTCGTTT
TT-30 for VEGFA and 50-CGGCTACCACATCCAAGG
AA-30 and 50-GCTGGAATTACCGCGGCT-30 for 18S
rRNA. Transcript levels of ANKRD37 were normalized
to 18S rRNA.
Western blotting
Cells were lysed in chilled lysis buﬀer (20mM Tris–HCl,
pH 7.5, 150mM NaCl, 1mM Na2EDTA, 1mM EGTA,
1% Triton, 2.5mM sodium pyrophosphate, 1mM b-gly-
cerophosphate, 1mM Na3VO4, 1mM leupeptin) supple-
mented with the Complete protease inhibitor cocktail
(Roche). Total 50mg of protein extracts were resolved
on a 3–8% NuPAGE Tris–acetate SDS polyacrylamide
gel (Invitrogen) and transferred onto a polyvinylidene
diﬂuoride membrane (Millipore). The blots were probed
with anti-HIF1A (Transduction Laboratories; 1:500)
and anti-b actin (Sigma; 1:100 000) antibodies.
Immunoreactive proteins were visualized using the
Western Lighting Chemiluminescence Reagent Plus
(PerkinElmer Life Sciences).
Plasmid constructions
Fragments from  325bp to +230bp (promoter 1)
 166bp to +230bp (promoter 2) or  78bp to +230bp
(promoter 3) relative to the transcriptional start site of the
human ANKRD37 promoter were ampliﬁed by polymer-
ase chain reaction (PCR) using 1mg of human genomic
DNA extracted from DLD-1 cells. The PCR primers
were as follows:  325bp sense primer; 50-AACCAAAC
GCGTCCAGTTTCCTGGTTACGTG-30,  166bp sense
primer; 50-AACCAAACGCGTTCTCACGCCCACTGA
CTTA-30,  78bp sense primer; 50-AACCAAACGCGTA
TCCACAGCTGGCCAATCG-30 and +230bp antisense
primer; 50-GTGGTTGAGATCTTAAGGCAGATGAC
AAGAGTCC-30. The PCR-ampliﬁed products were
digested with MluI and BglII and subcloned into the
pGL3-basic vector (Promega). Site directed mutations
were introduced at three potential HIF-binding sites
(1, 2 and 4). To prepare site 1 and site 4 mutants, the
 325 ANKRD37-luc pGL3 plasmid was digested with
MluI/PstI or PmlI/Tth111I, respectively, and ligated
with a double-stranded oligonucleotide in which the con-
sensus HIF-binding site was disrupted. The oligonucleo-
tide sequences were as follows: 50-CGCGTCCAGTTTCC
TGGTTAAAAGCGCGCCGGCAGAGCCAAAACC
TGCA-30 and 50-GGTTTTGGCTCTGCCGGCGCGCT
TTTAACCAGGAAACTGGA-30 for site 1 at  310bp
and 50-GTGCCAGTGTTTGTGTAAAAGCGGCCGT
GGCGGGGCTGGACA-30 and 50-CTGTCCAGCCCC
GCCACGGCCGCTTTTACACAAACACTGGCAC-30
for site 4 at +14bp. To prepare the site 2 mutant, PCR-
based site-directed mutagenesis was performed using
primers 50-TACCGGGAGAAAAGTCAAACTCA-30
and 50-TGAGTTTGACTTTTCTCCCGGTA-30. The
nucleotide sequences of all constructs were conﬁrmed by
sequencing.
Transfections and reporter assays
Transient transfections were performed using Fugene 6
(Roche) in 24-well tissue culture plates according to the
manufacturer’s speciﬁcations. Total 150ng of ANKRD37-
luciferase pGL3 reporter constructs were co-transfected
with 2ng of pRL-CMV (Promega) as a control. Ten
hours after transfection, the culture medium was switched
to UltraCulture and cells were grown in normoxic or
hypoxic conditions for 18h. Luciferase activity was mea-
sured with a dual luciferase reporter assay system
(Promega). The experiments were performed in triplicate
wells a minimum of three times.
RNA interference
HCT116 cells were transfected with 20 nM siRNA duplex
oligos directed to HIF1A or a non-speciﬁc control siRNA
using Lipofectamine RNAiMAX (Invitrogen) according
to the manufacturer’s instructions. Nucleotide sequences
of siRNAs were as follows: HIF1A,5 0-r(AUCCAGAGUC
ACUGGAACU)d(TT)-30, and control, 50-r(GCGCGCU
UUGUAGGAUUCG)d(TT)-30. The silencing eﬀect was
conﬁrmed by Western blotting 48h after transfection.
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Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from MCF7 cells cultured
in either normoxic or hypoxic conditions for 12h utilizing
NE-PER nuclear extraction reagent (Pierce). The
ANKRD37 promoter sequence utilized as an oligonucleo-
tide probe was 50-CTACCGGGAGACGTGTCAAACTC
AG-30. The 50-end of the oligonucleotide was labeled with
biotin, and a complementary oligonucleotide was
annealed to generate double-stranded fragments. EMSA
was performed using LightShift chemiluminescent kit
(Pierce) as previously described (54). Speciﬁcity of shifts
was conﬁrmed by utilizing 200-fold molar excess of unbio-
tinylated oligonucleotides as a speciﬁc competitor.
Mutagenesis was performed to further deﬁne the elements
responsible for the speciﬁc shifts obtained. The sequence
of the mutant oligonucleotide probe that includes point
mutations in the HIF consensus-binding site was: 50-CT
ACCGGGAGAAAAGTCAAACTCAG-30.
Chromatin immunoprecipitation (ChIP)
MCF7 cells were cultured in either normoxic or hypoxic
conditions for 6h and then ﬁxed with 1% formaldehyde at
378C for 10min. The ChIP assays were performed using a
Chromatin Immunoprecipitation Assay Kit (Upstate)
according to the manufacturer’s protocol. Brieﬂy, cells
were lysed and sonicated to achieve DNA sizes ranging
from 200 to 1000bp. Diluted supernatants were pre-
cleared by incubating with salmon sperm DNA/protein-
A agarose, 50% slurry at 48C for 30min. Supernatants
were then incubated with anti-HIF-1a antibody (Novus
Biologicals number 100–105) or normal mouse IgG
(Santa Cruz) at 48C overnight, or directly processed to
the next step without antibody. Immunocomplexes were
collected with salmon sperm DNA/protein A-agarose,
50% slurry, washed, eluted and cross-linkage was reversed
by heating at 658C for 4h. The eluates were then digested
with proteinase K at 458C for 1h. The precipitated DNAs
were recovered using PCR Puriﬁcation Kit (Qiagen)
and ampliﬁed by PCR using PrimeSTAR HS DNA Poly-
merase (Takara Bio). The PCR primers used for ampli-
ﬁcation of site 2 (primers A) and a non-HIF region
upstream of site 2 (primers B) were as follows: sense
primer A; 50-CCAGTTTCCTGGTTACGTGC-30, anti-
sense primer A; 50-TAAGTCAGTGGGCGTGAGAG-30,
sense primer B; 50-TGGAGGCACTTTCACCACAC-30
and anti-sense primer B; 50-TGTGAGGTGAGCACAC
GTTG-30.
RESULTS
HIF-1 and HIF-2 and their downstream-target genes are
activated in response to hypoxia. To identify HIF-target
genes we ﬁrst identiﬁed genes that responded to hypoxia
using publicly available microarray data sets. NCBI GEO
and EBI ArrayExpress were searched for experi-
ments where the same tissue was proﬁled comparing nor-
moxia and hypoxia. Experiments that used replicates,
were proﬁled on Aﬀymetrix platform and provided raw
data were accepted for further analysis (Supplementary
Table S1). The same identical analysis protocol was
applied to all experiments (see ‘Materials and Methods’
section). Although all microarrays were proﬁled on
Aﬀymetrix arrays, the number of genes diﬀerentially
expressed in each cell type varied signiﬁcantly and
ranged from 486 genes in monocytes to 2119 genes in
HeLa, with a surprisingly small overlap. The diﬀerentially
expressed genes in each cell type are the potential HIF-
target genes and were subject to in-silico analysis of HIF-
binding sites.
In-silico optimization of HIF-binding site prediction
Two databases of PWMs were obtained and searched for
HIF-1 PWM. The Jaspar collection (v3.0) contained no
HIF-1 PWM while the TRANSFAC collection (v8.2) con-
tained 2 HIF-1 PWMs (M00466, M00797). These PWMs
are 12 and 14 bases long and were compiled based on only
12 and 23 validated binding sites, respectively. We com-
piled an additional HIF-1 PWM based on 104 validated
binding sites in human, mouse and rat collected by
Wenger et al. (10) (see Supplementary Figure S1; sub-
mitted to Jaspar). Despite the apparent variability in
PWM length, it is clear from the alignment in
Supplementary Figure S1 that most of the information
content is within the HIF consensus binding site:
RCGTG. The composition preference in the region ﬂank-
ing the core RCGTG observed in the Transfac matrices is
a consequence of using a small number of validated HIF-
1-binding sites.
Proximal promoters were deﬁned from 700 bases
upstream to 300 bases downstream of the transcription
start site (TSS) of each transcript. Initially, HIF-1
PWMs were used to identify binding sites; however, we
observed a too small overlap between the three HIF-1
PWMs for any given P-value and conservation ﬁltering
criteria. Diﬀerences in PWM length (12–18bp) and in
the sequences ﬂanking the consensus binding site were
found to introduce a bias in HIF-1-binding-site prediction
since calculation of P-values and conservation consider
the entire length of the matrix and all bases deﬁned
within. To avoid this bias all HIF consensus-binding
sites sequences (RCGTG) were extracted from each pro-
moter and tested for conservation in other species (see
‘Materials and Methods’ section). A shift from A to G
and vice versa in the ﬁrst position was allowed for the
purpose of conservation. Next, the software site-cons in
CREAD was employed to calculate the level of conserva-
tion at each binding site compared to the ﬂanking 100
bases. A site was predicted as a HIF-binding site if it
was conserved in at least 10 species (including human)
or if conserved in four species with a site-cons P<0.05.
When the HIF consensus site is preceded by a C, it may
form the E-box-binding site CACGTG which is a known
binding site for several bHLH transcription factors includ-
ing HIF-1. In 43% of the E-box sites other TFs were
predicted to bind at the same location as HIF-1, compared
to only 2% of the non-Ebox sites. The transcription
factors that are most commonly predicted at the same
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AHR:ARNT, MYC, MAX, MYCN, CLOCK:ARNTL
and USF1 (Supplementary Figure S2). We only accepted
genes with at least one non-Ebox HIF site as HIF-target
genes. Throughout this strategy our ﬁltering criteria
were very stringent in order to obtain a catalogue of
high conﬁdence at the expense of not recovering some
known HIF targets. Each gene was scored as follows:
HIF site score ¼ Number of species
 ð logðconservation P valueÞÞ
Hypoxia score ¼ abs
X Hypoxia
Normoxia
     
The hypoxia/normoxia ratio was inverted and assigned
a negative value for genes that were downregulated in
hypoxia. Each gene was assigned two ranks, one based
on the highest scoring HIF site and one on the hypoxia
score. Finally, the sum of both ranks was calculated and
all genes were ranked based on that value. For instance,
the gene BNIP3, a bona ﬁde HIF-1 target, was ranked 515
by HIF site score and 15 by hypoxia score. Using the sum
of ranks BNIP3 was ranked 56 among all genes. This
scoring scheme is biased towards genes that respond to
hypoxia in multiple cells. While some genes could be
HIF targets in only one cell, we reason that a gene that
responds to hypoxia in more than one cell is more likely to
be a HIF target. This strategy is summarized in Figure 1.
Despite the stringent selection criteria of this approach we
were able to identify a HIF-binding site in 35/86 promo-
ters of known target genes. A list of previously identiﬁed
known HIF-1-target genes is shown in Supplementary
Table S2.
The majority of hypoxia responsive genes lack a
HIF-binding site
HIF-target genes were predicted for each data set sepa-
rately with the criteria outlined in ‘Materials and
Methods’ section. Of the known and validated HIF-
target genes that responded to hypoxia in each data set,
we recovered 37–55% (Table 1). On average 70% of the
hypoxia responsive genes did not contain a detectable
HIF-binding site in their proximal promoter (Table 1).
To verify this observation and to test that no bias was
introduced by our stringent conservation ﬁltering above,
genes that responded to hypoxia in each data set were
divided to two groups. Those with a predicted HIF-bind-
ing site (A) and those with no detectable HIF-binding site
(B). Each group was tested for over-representation of any
PWM compared to a random set of promoters with sim-
ilar base composition and CpG content. This analysis was
performed using the program MOTIFCLASS in CREAD
and is independent from the prediction analysis and selec-
tion criteria outlined above. In addition, MOTIFCLASS
does not consider conservation and is based on sequence
analysis alone. As expected HIF PWMs were identiﬁed
in the top 20 over-represented binding sites in group
A and none of the HIF PWMs were detected in the top
20 PWMs from group B. The results for the top 20
enriched motifs in each group in MCF7 breast cancer
cells are shown in Figure 2A and B. The highest
scoring PWM was a HIF-1 matrix that had a classiﬁca-
tion error of 0.407. In each of the six data sets we
observed HIF-1 enrichment in group A while group B
varied signiﬁcantly between cell types (Supplementary
Table S3). We did not observe any signiﬁcant HIF enrich-
ment within the top 20 PWMs in group B throughout all
data sets.
The general response to hypoxia is dependent on a small
number of genes
Previous studies have suggested that the response to
hypoxia varies by cell type (55–57). However, we expected
a core set of genes to be shared, e.g. genes that control the
shift from oxidative to glycolytic metabolism and inhibi-
tion of cellular proliferation. Yet, the cellular response
to hypoxia was surprisingly selective between cells. Only
17 genes responded to hypoxia in all studied cell types.
These genes include HIF targets such as ENO1,
BHLHB2 and BNIP3. We observed a positive correlation
between the number of cells in which a gene responded
to hypoxia and the identiﬁcation of HIF-binding sites in
its promoter (Figure 2C). Only 23% of the genes that
responded to hypoxia in a single cell type had a predicted
HIF-binding site in their promoter compared to 59% of
the genes that responded in six cell types. The top scoring
gene was TMEM45A which responded to hypoxia in all
studied cell types with an average of 21.6-fold induction
and a HIF-binding site conserved in 13 species with a
conservation P-value <0.0001 compared to the ﬂanking
100bp. At least 5 of the top 10 genes have been previously
identiﬁed as HIF-1-target genes, namely DDIT4 (58,59),
STC2 (60), P4HA1 (61), JMJD1A (62) and ALDOC (63).
We did not ﬁnd any correlation between the response to
hypoxia and the HIF-binding site score for the top 100
predicted HIF-target genes. To obtain a cutoﬀ of high
conﬁdence, the top 500 ranked genes were plotted versus
the cumulative number of previously validated HIF-1 tar-
gets (Supplementary Figure S3). The resulting curve
showed a logarithmic increase in validated targets for
genes ranking below 200 and approached saturation
between 200 and 500. Therefore, the 200th gene rank
was used as a cutoﬀ of high conﬁdence. Supplementary
Table S4 summarizes our prediction results for the top 500
HIF-target genes.
In the top 200 predicted HIF-target genes, 81 responded
to hypoxia in at least three cell types (Figure 3). We
hypothesize that these genes are likely to be part of the
core response to hypoxia. In addition, these genes have a
higher probability of being HIF-1 targets since their
response to hypoxia was detected in multiple experiments.
Of the 81 genes, 22 genes were previously reported to be
HIF-target genes and 60 genes (74%) were upregulated in
hypoxia. In addition, 80 (99%) of the genes contained a
CpG island in their proximal promoter, signiﬁcantly
higher than the 51% CpG containing promoters in our
entire promoter database. CpG islands are thought to be
non-tissue speciﬁc (64), further supporting the selection of
the 81 genes as a shared response to hypoxia. The Kyoto
Encyclopedia of Genes and Genomes (KEGG) database
4592 Nucleic Acids Research, 2009, Vol. 37,No. 14was used to identify over-represented pathways and pro-
cesses within the 81 genes. In Figure 4A a metabolic map
of HIF-1-target genes was constructed from the resulting
analysis (Supplementary Table S5). The metabolic map
contained several known HIF-1-target genes, such as
LDHA, ALDOC and GAPDH and also several novel tar-
gets such as GYS1 in starch and sucrose metabolism (65)
and fumarate hydratase (FH) in the TCA cycle (66).
One of the key cellular responses to HIF-1 in hypoxia is
a metabolic shift from oxidative phosphorylation to gly-
colytic production of ATP. To highlight direct targets that
may be involved in HIF-1 regulation of mitochondria
function the predicted HIF targets that localize to the
mitochondria (see ‘Materials and Methods’ section) were
used to create a mitochondrial map (Figure 4B). Eight
of eleven genes were downregulated in hypoxia and
are involved in critical steps of mitochondrial function
including two ribosomal subunits, cytochrome c, the
iron transporter SLC25A28 and the iron–sulfur assembly
and repair protein ISCU.
Classification of novel HIF targets
All previously validated HIF-1 targets (Supplementary
Tables S2 and S4) were tested for functional enrichment
in KEGG pathway databases, Reactome database, Gene
Set Enrichment Molecular Database (GSEA), protein
interactions, InterPro protein domains and microRNA-
target prediction database TargetScan (see ‘Materials
and Methods’ section). This analysis allows identiﬁcation
of pathways or attributes that are highly represented by
the HIF targets compared to an equivalent random list
of genes. We next mapped novel HIF targets to these
signiﬁcantly enriched attributes as demonstrated by
selected examples in Table 2 (full analysis shown in
Supplementary Table S6). Analysis of protein domains
identiﬁed 2-oxoglutarate and Fe(II)-dependent oxygenase
family as highly enriched in validated HIF targets (5 of 19
proteins, P<2e–7). This family includes the prolyl hydro-
xylases known to regulate HIF-1a as part of the oxygen
sensing mechanism. PLOD1, is a novel predicted HIF
target that is part of the same family. Analysis of
microRNA targets identiﬁed ﬁve microRNAs that target
validated HIF targets. miR-1/206, for instance, is pre-
dicted to target 583 human genes, of which nine are
known to be HIF-1 targets and 14 are predicted HIF
targets. Analysis of gene sets from GSEA highlighted
a group of 104 genes that predict a poor breast cancer
prognosis and included nine validated HIF targets
(P=1e–7) and four predicted ones. A graphical represen-
tation of protein interactions and Reactome pathways is
shown in Figure 4C and D and highlights genes such as
PCAF. PCAF interacts with four validated HIF targets
and six predicted targets.
ANKRD37 is a novel HIF-target gene
To demonstrate the utility of our method in identifying
novel HIF-1-target genes, we selected ﬁve genes that were
previously unknown to be HIF-1 targets, ANKRD37
(ranked 8), KLF10 (ranked 24) WSB1 (ranked 32),
GYS1 (ranked 34) and ELL2 (ranked 465). Using quanti-
tative PCR, ANKRD37 was induced up to 35-fold in
hypoxia compared to normoxia, KLF10 up to 2.5-fold,
WSB1 up to 4.9-fold, GYS1 up to 7.8-fold, ELL2 was
not induced in hypoxia and VEGFA that was used as a
positive control was induced up to 8.3-fold (Figure 5 and
Supplementary Figure S4A). The gene ANKRD37 was
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Figure 1. Prediction strategy for identifying HIF-1-target genes. Candidate genes that respond to hypoxia were ﬁrst identiﬁed by microarrays. Each
data set was subjected to a computational analysis in which HIF-binding sites were detected in proximal promoters. Each gene was scored for its
response to hypoxia and for the best HIF-binding site. No cutoﬀ was set for determining HIF-target genes. Finally, all genes were ranked.
Table 1. Transcriptional response to hypoxia across six diﬀerent cell types as determined by microarrays
MCF7 U251 Astrocytes Monocytes B cells HeLA
Genes that respond to hypoxia 830 1702 1371 486 1920 2119
Genes that respond to hypoxia in which a
HIF binding site was identiﬁed
278 (33%) 546 (32%) 380 (28%) 159 (33%) 534 (28%) 555 (26%)
Known target genes that respond to hypoxia 35 31 20 22 32 27
Known target genes recovery 19 (54%) 17 (55%) 8 (40%) 11 (50%) 13 (41%) 10 (37%)
Nucleic Acids Research, 2009,Vol.37, No. 14 4593studied further due to its extreme induction in hypoxia
and its high ranking within the predicted targets.
ANKRD37 is a short (158 amino acids, 17kDa) ankyrin
repeat protein with unknown function that is conserved in
mammals and zebraﬁsh. ANKRD37 responded to hypoxia
in four of six cell types and four HIF-1-binding sites were
predicted within the proximal promoter. The response to
hypoxia was validated under hypoxic conditions across
seven cell lines. We observed a strong induction of
ANKRD37 in all cell lines but most signiﬁcantly in the
colon cancer cell lines DLD-1, HCT116 and SW480
(Figure 5A). ANKRD37 hypoxic induction was measured
after 4, 8 and 12h of incubation in hypoxic conditions in
HCT116 cells and compared to VEGFA. HIF-1 protein
levels were determined by western blot and showed a sig-
niﬁcant induction after 4 and 8h compared to normoxia
and a slight decrease after 12h (Figure 5B). ANKRD37
and VEGFA mRNA levels showed a similar proﬁle that
matched the HIF-1 induction; however, ANKRD37 was
induced 3-fold over the level of VEGFA induction
(Figure 5C).
We next investigated the HIF-binding sites in the
ANKRD37 promoter. We identiﬁed four HIF-1-binding
sites that matched our ﬁltering criteria and were located
at  311 to  306bp (site 1),  228 to  223bp (site 2),  142
to  137bp (site 3) and +12 to +17bp (site 4). As shown
in Figure 6A, three ANKRD37 promoters encompassing
these diﬀerent HIF-binding sites were cloned upstream of
a luciferase reporter. Promoter 1 was induced 4.1, 7.4 and
10.7-fold in hypoxia compared to normoxia in DLD-1,
HCT116 and MCF7 cells, respectively. In contrast the
induction observed with promoters 2 and 3 was in the
range of 1.5–3-fold (Figure 6B). To determine whether
the hypoxia induction was HIF-1 dependent, luciferase
activity of ANKRD37 promoter 1 was measured in
HCT116 cells in the presence of HIF1A siRNA.
Endogenous HIF1A knockdown was conﬁrmed by west-
ern blot (Supplementary Figure S4A). The 5-fold induc-
tion of promoter 1 in hypoxia was reduced to 1.3-fold
in the presence of HIF1A siRNA (Supplementary
Figure S4B). These results suggested that sites 1 and 2
are the physiologically relevant HIF-1-binding sites.
Therefore, sites 1, 2 and 4 in promoter 1 were selectively
mutated at the HIF consensus-binding site (ACGTG >
AAAAG). As shown in Figure 6C, the hypoxic induction
of promoter 1 was maximally inhibited by a mutation in
site 2 while the other mutations had a minimal eﬀect.
To establish whether endogenous HIF-1 protein binds
to site 2 in the ANKRD37 promoter, EMSA assays were
performed using nuclear extracts from MCF7 cells
Figure 2. (A and B) Binding site enrichment analysis. The program
MOTIFCLASS was employed to identify binding sites signiﬁcantly
over-represented in the promoters of genes that respond to hypoxia
in B cells. (A) Totally 770 promoters of genes that responded to
hypoxia in which a detectable HIF-1-binding site was identiﬁed. HIF-
1 PWMs were identiﬁed as the most enriched. (B) Totally 1456 pro-
moters of genes that responded to hypoxia but do not contain a detect-
able HIF-1-binding site. No HIF-1 PWM was identiﬁed in the top 20
matrices. Sn, sensitivity; Sp, speciﬁcity; Error, classiﬁcation error rate;
Pval, P-value. (C) Correlation between the number of HIF-target genes
and the number of cells in which they responded to hypoxia. Only 31%
of the genes that responded to hypoxia in one of six cells was predicted
as a HIF-target gene, compared to 71% of the genes that responded to
hypoxia in six of six cell lines.
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Figure 3. HIF dependent response to
hypoxia across six cell types for 81 selected
genes that respond to hypoxia in at least
three cell types and were ranked within
the top 200 HIF-target genes. The heatmap
shows a fold induction compared to nor-
moxia within each cell type. White blocks
indicate the gene did not respond to
hypoxia in that cell type.
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Figure 4. (A) Metabolic map of HIF-target genes. The KEGG pathway database was employed to
map 81 HIF-target genes deﬁned as the core response to hypoxia to pathways. Metabolism related
processes are shown here (black objects) and those over-represented with a P<0.05 are shown with
a dotted white frame. Upregulated genes are shown as red nodes while downregulated genes as green
nodes. Previously identiﬁed HIF-1-target genes are indicated by a diamond shape. (B) Mitochondrial
map. Genes within the top 200 predicted HIF targets that localize to the mitochondria were mapped
according to their functional annotation. Upregulated genes are shown as red nodes and down-
regulated as green nodes. Genes indicated in bold responded to hypoxia in at least three cell types.
Dotted lines from iron–sulfur protein assembly and repair illustrate a few of the iron–sulfur proteins
that are key to mitochondrial function, such as NADH dehydrogenase. (C) Graphical representation
of protein-protein interaction network and Reactome pathways (D) enrichment for previously vali-
dated HIF-1 targets (red) and novel predicted targets (yellow). Only proteins/pathways that were
signiﬁcantly enriched (P<0.05) are shown. See Supplementary Table S6 for analysis details.
Nucleic Acids Research, 2009,Vol.37, No. 14 4595incubated in either normoxia or hypoxia. A unique band
shift was obtained only when nuclear extracts from cells
grown in hypoxic conditions were incubated with the
probe corresponding to site 2 (Figure 6D, lane 3). When
non-biotinylated probe was co-incubated as a competitor,
or a probe with speciﬁc mutations in the HIF consensus-
binding site (ACGTG > AAAAG) was utilized, the band
obtained in hypoxic conditions was lost (Figure 6D, lanes
4 and 5). Nuclear extracts from cells grown in hypoxia
were then incubated with an antibody speciﬁc to HIF-1a
or control mouse IgG prior to performing EMSA assays.
Incubation with an antibody against HIF-1a resulted in a
supershift of this speciﬁc band (Figure 6E). To further
address whether HIF-1a physiologically binds to site 2,
chromatin immunoprecipitation assays were performed
using MCF7 cells incubated in either normoxia or
hypoxia. Cross-linked cell lysates were immunoprecipi-
tated with or without anti- HIF-1a antibody or control
mouse IgG and PCR was performed to amplify a 178bp
or 220bp fragment of the ANKRD37 promoter using pri-
mers corresponding to site 2 (primers A) and a region
upstream of site 2 (primers B), respectively. DNA bound
to HIF-1a was detected when DNA–protein complexes
from hypoxic cells were precipitated with an anti-HIF-
1a antibody and ampliﬁed with primers A, whereas no
binding was observed at an upstream promoter region
with primers B (Figure 6F). These data indicate that site
2, the most conserved and highest scoring HIF site, is
indeed a HIF-1-binding site in DLD-1, HCT116 and
MCF7 cells.
The HIF-transcriptional network
To identify transcription factors that are part of the HIF
network we analyzed the presence of other binding sites in
the 81 genes that ranked in top 200 and responded to
hypoxia in at least three cell types. Matrices for validated
transcription factors from the TRANSFAC and Jaspar
collections were used to identify binding sites within 150
bases away from the highest scoring HIF-binding site
in each of the promoters as well as within the entire pro-
moter. For this analysis we used STORM with P<1e–4
and accepted only binding sites predicted in at least four
species and signiﬁcantly (P<0.05) more conserved com-
pared to the ﬂanking 100 bases (see ‘Materials and
Methods’ section). To obtain a P-value for co-occurring
binding sites, a chi-square analysis was performed com-
pared to TFBS occurrence in a background set of 1000
promoters of genes that responded to hypoxia in at least
one cell type but had no detectable HIF binding (see
Table 2. Selected examples of functional enrichment of 101 previously validated HIF-1 targets and mapping of novel targets to these categories
Source Description Number of genes Previously validated HIF-1 targets Novel HIF-1 targets
P-value Gene symbols
Protein domains IPR005123; 2-oxoglutarate
(2OG) and Fe(II)-
dependent oxogenase
6/19 2.E-07 P4HA2, EGLN3, EGLN1,
P4HA1, PH-4
PLOD1
GSEA Poor progonosis marker
genes in Breast Cancer
13/104 1.E-07 CA9, CP, PGK1, EGLN1,
TFRC, VEGFA, NDRG1,
ADM, BNIP3
TMEFF1, IVNS1ABP,
TMEM45A, RRAGD
KEGG Arginine and proline
metabolism
6/35 4.E-05 P4HA2, NOS3, P4HA1,
NOS2A
EPRS, ALDH4A1
Reactome Platelet activation 7/86 1.E-02 PDGFA, TGFB3, FN1,
VEGFA, ALDOA,
SERPINE1
ARHGEF1
TargetScan MiR-1/206 23/583 3.E-03 PDGFA, NAMPT, HSP90B1,
MET, ETS1, VEGFA,
EDN1, CITED2, STC2
RNF165, GRK6, SLC7A6,
PTPLAD1, ASPH,
MYLK, RSBN1,
SLC31A1, EVI1,
PGAM1, SOX6, BTAF1,
MXD1, GLCCI1
Protein interactions PCAF 10/106 9.E-05 ENO1, NR4A1, PFKL, PGK1 RARA, CCNB1, SSRP1,
RBPJ, EVI1, BTAF1
The number of genes reﬂects the total number of known and predicted targets within the functional group. P-values for enrichment of validated
HIF-1 targets were obtained using the hypergeometric distribution as described in ‘Materials and Methods’ section.
A
C B
Figure 5. ANKRD37 response to hypoxia. (A) ANKRD37 mRNA levels
were monitored by qPCR across seven cell lines and normalized to 18S
rRNA. (B, C) ANKRD37 hypoxic induction over time during hypoxia.
(B) Endogenous HIF1A protein levels determined after 0, 4, 8 and 12h
of hypoxic incubation by western blot. (C) mRNA levels of ANKRD37
and VEGFA measured by qPCR after 0, 4, 8 and 12h of hypoxic
incubation.
4596 Nucleic Acids Research, 2009, Vol. 37,No. 14Figure 6. Mapping of HIF-1 site in ANKRD37 promoter. (A) Genome browser view of the four HIF-binding sites identiﬁed in the ANKRD37
promoters and the three promoter sequences that were cloned to identify the dominant HIF-1 site. The site score is shown in parenthesis for each
site, higher is better. The larger box of the ANKRD37 transcript (green) indicates the coding sequence. Note that the conservation shown on the plot
is computed by PhastCons which scores conservation based on the evolutionary distance and does not necessarily reﬂect the number of species (95).
(B) DLD1, HCT116 and MCF7 cells were transiently transfected and incubated under normoxic or hypoxic conditions. Luciferase activity of the
three promoters was measured and normalized to promoter 1 in normoxic conditions. All studies were performed in triplicate and data represent the
mean   SD for three diﬀerent wells. (C) Luciferase activity of promoter 1 in normoxia versus hypoxia with mutations in sites 1, 2 and 4 in DLD1,
HCT116 and MCF7 cells. Experimental procedure and data analysis was performed as described for panel B. (D) In vitro binding of HIF-1 protein
to site 2 in the ANKRD37 promoter. EMSAs were performed using biotinylated probe corresponding to HIF-binding site 2. Nuclear extracts (NE)
from MCF7 cells cultured in either normoxia (N) or hypoxia (H) were utilized. The asterisk indicates the speciﬁc shift obtained in hypoxia. 200  M
excess of non-labeled probe as a speciﬁc competitor or probe with a speciﬁc mutation in the HIF-binding site2 (ACGTG > AAAAG) was utilized to
conﬁrm speciﬁcity. WT=wild-type probe. MT=mutant probe. (E) Nuclear extracts from MCF7 cells grown in hypoxia were incubated with
antibody speciﬁc to HIF-1a or normal mouse IgG. The double asterisk indicates the super-shift obtained only with a HIF-1a antibody. N.S.;
nonspeciﬁc band. (F) In-vivo binding of HIF-1a protein to site 2 in the ANKRD37 promoter. ChIP assays were performed using primer sets
corresponding to HIF-binding site 2 (primer A) or a region upstream of site 2 (primer B). DNA–protein complexes from MCF7 cells cultured in
either normoxia (N) or hypoxia (H) were immunoprecipitated with or without antibody speciﬁc to HIF-1a or normal mouse IgG. Precipitated DNA
or input samples were ampliﬁed by PCR.
Nucleic Acids Research, 2009,Vol.37, No. 14 4597‘Materials and Methods’ section). The analysis was per-
formed in increments of 25 bases from the highest scoring
HIF site and the most signiﬁcant P-value for each PWM
was selected. Only binding sites that were not predicted at
the HIF consensus binding site were considered. We iden-
tiﬁed 10 TFBS that were signiﬁcantly enriched within a
speciﬁc distance from the highest scoring HIF site includ-
ing ATF2, CREB1, SP1, WT1 and JUN which have been
previously linked to hypoxia and HIF-1 (Supplementary
Table S6). When considering the entire promoter, we
observed enrichment for P53:P73-binding sites and multi-
ple members of the forkhead family, including FOXO4,
FOXD1 and FOXF2. To test for potential mechanism in
up or down regulation of HIF-target genes, a similar ana-
lysis was employed to upregulated and downregulated
transcripts separately. Most of the sites co-occurring for
all HIF targets above were also enriched for the upregu-
lated genes, albeit with more signiﬁcant P-values. SP-1
and NF-Y were the only TFs signiﬁcantly co-occurring
within a speciﬁc distance from the HIF site in downregu-
lated genes. Surprisingly, four of ﬁve predicted NF-Y tar-
gets (ABCF2, CYCS, FH, MRPL4) were genes localized
to mitochondria (Supplementary Table S7).
HIF-1 motifs are identified de-novo in predicted
HIF-1-target genes
To identify de-novo motifs over-represented in the pro-
moters of the 81 HIF-target genes selected above,
DME2 was employed. For each motif length in the
range of 5–12 bases we identiﬁed the top 50 over-repre-
sented motifs compared to a suitable background set (see
‘Materials and Methods’ section). These motifs were com-
pared to the TRANSFAC and Jaspar collections of
PWMs using the CREAD program MATCOMPARE.
Comparison was estimated using a divergence score in
the range of 0 to 1, where a divergence of 0 indicates the
motif predicted de-novo is identical to a PWM. HIF-1
PWMs were matched best to six bases long de-novo
motifs. For motifs longer than 7 bases, no HIF-1 PWMs
were ranked within the top 50 (Supplementary Table S8).
Comparing all available PWMs to de-novo predicted
motifs with a divergence of 0.25 or lower identiﬁed
ARNT (HIF-1b), ATF2, NF-Y and ATF6 as the most
enriched in the data set (Supplementary Table S9).
Other motifs that were predicted de-novo include
CREB1, AP-1 and EVI1 and MIZF (Supplementary
Table S9). Some of these are also identiﬁed above as
part of the HIF-transcriptional network.
DISCUSSION
In this study we presented a computational strategy to
identify HIF-1-target genes. This strategy integrates gene
expression proﬁles and computational-binding site analy-
sis of proximal promoters. The utility of our strategy in
detecting novel HIF-target genes was demonstrated by
recovering known HIF-1-target genes and experimentally
validating ANKRD37. ANKRD37 is a previously unchar-
acterized protein that contains four ankyrin repeats.
Ankyrin repeats are thought to mediate protein–protein
interactions (67) and are known to be involved in regula-
tion of key transcription factors such as NFkB and TP53
(68–70). ANKRD37 induction was 3-fold higher than
VEGFA (Figure 5E), the validated HIF-1-binding site
was conserved in 10 species and was signiﬁcantly induced
in hypoxia in multiple cell types analyzed here. Taken
together, these data suggest ANKRD37 is likely to have
an important role in the hypoxia response.
The cellular response to hypoxia was diﬀerent between
cell types, consistent with previous reports (55,56).
The union of all diﬀerentially expressed genes in the
data sets presented here contained over 6000 unique
genes. Even when comparing studies that attempted to
detect a HIF dependent response to hypoxia (21,22,71),
only 45 genes were diﬀerentially expressed in all three.
Importantly the analysis presented here indicates that
60% of the transcripts that responded to hypoxia did
not have a detectable conserved HIF-binding site in
their proximal promoter. This observation was also sup-
ported by MOTIFCLASS enrichment, which is an inde-
pendent analysis that does not consider conservation and
did not detect any enrichment for HIF-binding sites in
those promoters. In addition, transcripts with no detect-
able HIF site were enriched for other TFBS that were
previously shown to participate in the cellular response
to hypoxia including, DEAF1, ELK1, POU2F1 and
IRF1 (72,73). Moreover, genes that responded to hypoxia
and did not have a detectable HIF-binding site were
used as a background for the HIF-1-transcriptional net-
work. One possible mechanism that may explain the
diﬀerent hypoxic response between cells is that genes
directly regulated by HIF are involved in key processes
and their regulation mediates a robust eﬀect. As illustrated
in the mitochondrial map, where several predicted
downregulated genes aﬀect key steps in the mitochondria.
The predicted HIF-target genes SLC25A28, an iron trans-
porter in the mitochondria and ISCU, an iron–sulfur scaf-
fold protein are both downregulated in hypoxia. These
two genes could aﬀect several of the mitochondria iron–
sulfur proteins including, NADH dehydrogenease,
Coenzyme Q—cytochrome c reductase and Succinate—
coenzyme Q reductase are critical to the function of the
electron transport chain and the TCA cycle. In addition,
the predicted HIF targets MRPL4 and MRPS12 are com-
ponents of the mitochondrial ribosome that are required
for mitochondrial protein translation. Additional exam-
ples include cell growth arrest by inhibition of CAD,a
component of pyrimidine synthesis (74); RRP9, a compo-
nent of snoRNP predicted to participate in processing and
modiﬁcation of pre-ribosomal RNA (75); EIF2B3,a
translation initiation factor subunit; and CCNB1, a regu-
latory protein involved in mitosis (74). One novel pre-
dicted HIF target that is highlighted by the HIF-1
KEGG metabolic pathways map is GYS1, a gene involved
in glycogen biosynthesis (65,76) that was validated as
responsive to hypoxia by quantitative PCR in multiple
cell types.
To highlight predicted HIF targets of interest and to
suggest potential functional roles for these targets, a bio-
informatics analysis of validated HIF targets was per-
formed and predicted targets that were not previously
4598 Nucleic Acids Research, 2009, Vol. 37,No. 14validated were mapped to the signiﬁcantly enriched func-
tional categories. This analysis is summarized in
Supplementary Table S6 and identiﬁes several attractive
predicted HIF targets. The family of 2-oxoglutarate and
Fe(II)-dependent oxygenase has 19 members in the human
genome of which ﬁve are bona ﬁde HIF targets, including
the HIF-1a regulators EGLN1 and EGLN3. The predicted
HIF target PLOD1, is a member of that family and a lysyl
hydroxylase involved in collagen synthesis and localized to
the endoplasmic reticulum (77). Mutations in PLOD1
have been associated with type VI Ehlers–Danlos syn-
drome, a genetic disorder caused by defects in collagen
synthesis (78). In another example, microRNA-target pre-
dictions from TargetScan were analyzed and validated
HIF targets were enriched for ﬁve microRNAs including
miR-1/206 and miR-130/301. miR-1/206 were shown to be
upregulated in a rat model of myocardial infarction (79)
and miR-130 was shown to regulate angiogenesis (80).
Both are relevant to the HIF pathway and would be
attractive candidate microRNAs to study further with
respect to the validated and predicted targets. Finally, pro-
tein interaction data presented in Figure 4C can be used to
identify potential regulators, co-factors or adapter pro-
teins that play a role in the HIF pathway. Finally, P300/
CBP-associated factor (PCAF) interacts with four vali-
dated HIF targets and six predicted targets. PCAF was
previously shown to be a HIF-1a co-factor that regulates
p53-transcriptional activity in hypoxia (81). The speciﬁc
HIF targets that interact with PCAF are attractive candi-
dates for functional studies.
The method presented here is not without limitation.
First, the microarray itself presents a limitation since
only genes represented on the microarray are considered.
However, this could be improved by using multiple plat-
forms that oﬀer complete coverage of annotated genes. Of
the 86 previously validated HIF-1 targets (Supplementary
Table S2), only 56 responded to hypoxia in at least one cell
type. One example of a bona ﬁde HIF-target gene that
was not recovered by our analysis is EPO (erythropoietin).
A close examination of the data for EPO revealed that the
probe did not respond to hypoxia in any of the cells that
were proﬁled. EPO was previously reported to be highly
induced in the kidney (82). Second, HIF-binding sites may
be located outside the promoter region we deﬁned or may
not be conserved in other species. The binding site for the
well-characterized HIF-1 target VEGFA is located at
 985bp (83) and therefore was not recovered in the pres-
ent analysis. HIF-1-binding sites have been identiﬁed as
far as 12-kb downstream (PHD3, (84) and 5-kb upstream
[eNos; (85)] of the TSS. The deﬁned promoter region was
found optimal to capture most of the known sites (60% of
known HIF-1-binding sites) while minimizing potential
false positive prediction.
In this study we provide a ranked catalogue of genes
predicted to be direct HIF-target genes. Given the diﬀer-
ent hypoxia response between cell types, it is currently
diﬃcult to estimate how many HIF-target genes exist.
Our analysis across six cell types was stringent in an
eﬀort to obtain the highest speciﬁcity and the top 200
ranked genes are of high conﬁdence. The ranking system
by itself oﬀers a level of conﬁdence for the prediction and
was shown as reliable by high ranking for previously vali-
dated targets (Supplementary Figure S3). Currently,
almost all known HIF-target genes are upregulated in
hypoxia. While the majority of predicted HIF targets
were upregulated in hypoxia, nearly all downregulated
genes are novel. The top ranking downregulated gene is
EDEM3,a na1,2-mannosidase involved in quality control
of misfolded proteins (86). In addition, a subset of down-
regulated genes highlighted in the mitochondrial map is
consistent with the observed attenuation of oxidative
phosphorylation by HIF-1 (87). We also identiﬁed NF-Y
as signiﬁcantly co-occurring adjacent to the highest scor-
ing HIF-1 site in four of these downregulated mitochon-
drial genes. It is currently unclear whether NF-Y is part
of the hypoxic regulation of those genes. However, it
was previously shown in yeast that the NF-Y homolog
regulates the mitochondrial enzyme COX (88), which
was also shown to be regulated by HIF-1 to optimize eﬃ-
ciency of mitochondrial respiration (89).
To describe the transcriptional network of HIF,
we identiﬁed additional TFBS over-represented within
 150bp from the highest scoring HIF site as well as
TFBS enriched in the entire promoter. We identiﬁed
only a few TFs within a speciﬁc distance from the HIF
site, however, almost all were previously associated with
HIF-1, including CREB1, ATF2 and SP1 (90–92). The
recovery of these TFs increases the conﬁdence in the
genes predicted as HIF targets and also identiﬁes speciﬁc
gene targets in Supplementary Table S6 as predicted tar-
gets with higher conﬁdence. WSB1, for instance, is a novel
predicted HIF-1 target that contains binding sites for
CREB1, ATF6, ATF2 and JUN:ATF2, a proﬁle very sim-
ilar to LDHA that is a bona ﬁde HIF-1 target. WSB1 was
previously shown to be involved in the ubiquitination and
degradation of HIPK2 (93), a kinase that was shown to
repress HIF-1a transcription (94). WSB1 was also con-
ﬁrmed to be hypoxia responsive by quantitative PCR
(Supplementary Figure S4). Taken together these data
suggest WSB1 is highly likely to be a direct HIF-1 target
and to be part of a feedback loop that includes HIF-1a,
WSB1 and HIPK2. TFs that were previously associated
with HIF-1 appear to be enriched only in genes upregu-
lated during hypoxia. YY-1 and NF-Y were detected as
enriched in downregulated genes. Further studies will be
necessary to validate these observations and to determine
their functional relevance to HIF-1.
De-novo motif prediction suggested that no signiﬁcant
information ﬂanking the HIF consensus-binding site
could be found in the predicted HIF-target genes. This
is consistent with the observation that enhancing the
number of validated HIF-binding sites reduces the
information content of the ﬂanking nucleotides
(Supplementary Figure S1). Conservation was not consid-
ered in the de-novo prediction process. Yet, several TFs
identiﬁed as part of the HIF-transcriptional network have
also been identiﬁed de-novo, including, CREB1,
JUN:ATF2, ATF2, ATF6 and AP-1. The ability to recover
these TFs de-novo conﬁrms their signiﬁcant over-represen-
tation and demonstrates the utility of this approach in
recovering previously validated TFs and co-factor that
are part of the HIF network. Furthermore, novel TFs
Nucleic Acids Research, 2009,Vol.37, No. 14 4599that may be part of the HIF-transcriptional network
are currently supported by sequence analysis data alone
and additional studies are required to validate these
ﬁndings.
HIF-1 and HIF-2 are both key transcription factors
with that modulate metabolic pathways, bioenergetics
and processes relevant to cancer onset and progression.
This study not only gives insights into the genes poten-
tially regulated by HIF but also serves as a guide to study
direct targets of other transcription factors.
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